Xingji Biopharmaceuticals

Xingji Biopharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative anti-infective therapies. The company focuses on addressing the global threat of antimicrobial resistance (AMR) by developing monoclonal and bispecific antibodies that target multi-drug resistant (MDR) bacteria and viral pathogens. Its lead candidate, XJ001, is a first-in-class bispecific antibody targeting Staphylococcus aureus toxins, currently undergoing Phase 2 clinical trials. Xingji's pipeline also includes XJ103, a bispecific antibody designed to treat Pseudomonas aeruginosa infections. By leveraging its proprietary antibody platform, the company aims to provide potent alternatives or adjuncts to traditional antibiotics for severe hospital-acquired infections.